LSE:AZNPharmaceuticals
AstraZeneca Balances CNS Partnering And Imfinzi Growth In Gastric Cancer
AstraZeneca (LSE:AZN) has in-licensed worldwide rights to a Phase 3 ready treatment-resistant schizophrenia asset, transferring development to biotech startup Amani Therapeutics.
The company also secured European approval for Imfinzi with FLOT chemotherapy in early-stage and locally advanced gastric and gastroesophageal junction cancers, supported by Phase III MATTERHORN trial data.
AstraZeneca, known for its broad oncology and biopharmaceutical portfolio, is adding fresh optionality on two...